US EditionPublished • loading... • Updated
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
- Esco Aster announced a cGMP manufacturing contract with Shine-On Biomedical for HLA-G targeted exosome drug delivery.
- Shine-On Biomedical's product SOB100 cleared the U.S. FDA IND review and is currently in a Phase I study.
- The collaboration enhances Esco Aster's position in Singapore's bioeconomy, enabling high yield at low GMP costs through innovative biomanufacturing.
Insights by Ground AI
58 Articles
58 Articles
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP…
Coverage Details
Total News Sources58
Leaning Left6Leaning Right6Center21Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 18%
C 64%
R 18%
Factuality
To view factuality data please Upgrade to Premium
